About NUCLEIS
NUCLEIS is a Healthcare company based in Liege (Belgium) founded in 2017, and was acquired by Curium in April 2025. PET radio-pharmaceutical drugs are manufactured under contract. The company has 13 employees. Its chief executive, as recorded, is Fabrice Giacomelli. Its focus areas include Biopharma Outsourcing, CDMO and Diversified.
Company details
NUCLEIS was established in 2017 in Liege, Belgium, where operations are centered on contract manufacturing within the nuclear medicine sector. PET radio-pharmaceutical drugs are produced for positron emission tomography applications in medical diagnostics. Services encompass formulation, synthesis, and quality control processes tailored to client specifications. The focus remains on regulatory compliance and supply chain efficiency for pharmaceutical partners across Europe.
- Headquarters Liege, Belgium
- Employees 13
- Stage Acquired
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website nucleis.eu
- Social LinkedIn
- Acquired by Curium (Apr 2025)
- Legal Name Nucleis
- Investors
- Employee Count13
- Acquired byCurium
(Apr 2025)
Investors in NUCLEIS
NUCLEIS has secured backing from 1 investor. Prominent investors backing the company include Curium Pharma.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Curium Pharma is recognized as a leader in radiopharmaceuticals. | 2017 | curiumpharma.com | Paris, France |
Investor details for NUCLEIS
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of NUCLEIS
1 people are tracked at NUCLEIS (1 in leadership); the tracked headcount is 13.
| Name | Role | Group |
|---|---|---|
Fabrice Giacomelli | CEO | Leadership |
Complete people profiles for NUCLEIS
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of NUCLEIS
2 dated milestones of NUCLEIS across 8 years, from founding to its latest funding, stage changes and deals.
- Founded NUCLEIS is founded.
- Exit Acquired by Curium.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about NUCLEIS
NUCLEIS was founded in 2017.
NUCLEIS is headquartered in Liege, Belgium. It is registered at Liege, Liege, Belgium.
Fabrice Giacomelli is the CEO of NUCLEIS, as recorded in our data.
NUCLEIS has 13 employees.
NUCLEIS was established in 2017 in Liege, Belgium, where operations are centered on contract manufacturing within the nuclear medicine sector. PET radio-pharmaceutical drugs are produced for positron emission tomography applications in medical diagnostics. Services encompass formulation, synthesis, and quality control processes tailored to client specifications. The focus remains on regulatory compliance and supply chain efficiency for pharmaceutical partners across Europe.
NUCLEIS has 1 investor. Key investors include Curium Pharma.
NUCLEIS operates through Nucleis.
Yes. NUCLEIS was acquired by Curium in April 2025.